MedTrace Logo

ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors

NCT03497624 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2020-09-09

No results posted yet for this study

Summary

Patient Derived Xenografts (PDXs) are models to study tumor growth, response to anti-cancer therapies, and resistance to anti-cancer therapies. The purpose of this study is to develop up to 24 PDX models for ROS1-fusion driven cancers to be used for research purposes only. That is, these patient derived PDX models will have no immediate benefit to the patient from whom the tumor specimen was obtained. Rather, these PDX models will be used to inform the study of ROS1-fusion driven cancers at large.

Conditions

  • ROS1-fusion Positive Tumor

Interventions

OTHER

Biospecimens collection

Collection of tumor tissue when a participant is having a clinically-indicated biopsy or surgery for their ROS1-fusion cancer.

Sponsors & Collaborators

  • Addario Lung Cancer Medical Institute

    lead OTHER

Principal Investigators

  • Christine Lovly, MD, PhD · Vanderbilt University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-23
Primary Completion
2020-09-04
Completion
2020-09-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03497624 on ClinicalTrials.gov